Table 2.
Infective Events According to Monoclonal Antibodies Administereda
| Total (n = 86) n (%) | Anti-CD20 (n = 28) n (%) | Anti-CD52 (n = 58) n (%) | P value (χ2 test) | |
|---|---|---|---|---|
| Recurrent IAE | 9 (11) | 4 (14) | 5 (9) | .325 |
| Etiology | ||||
| Bacterial | 31 (36) | 19 (68) | 12 (21) | <.001 |
| Viral | 49 (57) | 7 (25) | 42 (72) | <.001 |
| Fungal | 5 (6) | 2 (7) | 3 (5) | .527 |
| Severity | ||||
| Mild-moderate | 67 (78) | 20 (71) | 47 (81) | .314 |
| Severe | 19 (22) | 8 (29) | 11 (19) | — |
| Type of infection | ||||
| UTI | 23 (27) | 13 (46) | 10 (17) | .004 |
| RTI | 8 (9) | 6 (21) | 2 (3) | .013 |
| CMV reactivation | 42 (49) | 5 (18) | 37 (64) | <.001 |
| HSV or VZV reactivation | 4 (5) | 1 (4) | 3 (5) | .607 |
| Median time of onset (days) [IQR] | 31 [23–92] | 48 [10–103] | 30 [28–91] | .567 (Mann-Whitney test) |
| First month onset | 44 (51) | 12 (43) | 32 (55) | .284 |
| 2–6 months onset | 28 (33) | 10 (36) | 18 (31) | .664 |
| 7–12 months onset | 14 (16) | 6 (21) | 8 (14) | .274 |
| Immune status at infective event | ||||
| Median lymphocyte count [cells/μl, IQR] | 670 [250–1350] | 11205 [588–1580] | 5550 [220–910] | .007 (Mann-Whitney test) |
| Lymphocytopenia (<800 cells/μl) | 50 (58) | 9 (32) | 441 (71) | .001 |
| C4+ T-cell count < 200 cells/μl | 50/62 (81) | 110/13 (77) | 440/49 (82) | .485 |
| Median C4 T-cell countb [cells/μl, IQR] | 84 [22–177] | 1108 [0–427] | 178 [23–174] | .762 (Mann-Whitney test) |
| Median C8 T-cell countb [cells/μl, IQR] | 128 [41–231] | 1149 [0–271] | 1114 [47–235] | .986 (Mann-Whitney test) |
Abbreviations: CMV, cytomegalovirus; DMT, disease-modifying therapies; HSV, herpes simplex virus; IAE, infective adverse events; IQR, interquartile range; NS, not significant; RTI, respiratory tract infections; UTI, urinary tract infections; VZV, varicella zoster virus.
aData are expressed as number (percentage) or median (IQR).
bTwenty-four patient records missing (15 on anti-CD20 and 9 on anti-CD52).